Cromos Pharma Highlights Liver Cancer and Viral Hepatitis Awareness and Prevention Month
January is a Liver Cancer and Viral Hepatitis Awareness and Prevention Month that is aimed to educate people about liver diseases and to raise patient awareness about the risks of cancer and hepatitis and its available treatment modalities. At Cromos Pharma we are using this opportunity to underline our commitment to supporting clinical trials to develop new and innovative treatments and improve the lives of millions of people around the world who suffer from liver cancer and hepatitis.
Liver performs hundreds of functions related to metabolism, energy storage, and waste removal. At the same time, this organ can become quite vulnerable due to bad diet and unhealthy lifestyle.
Liver cancer affects more than 800,000 people throughout the world each year, about 25,000 men and 11,000 women are diagnosed with liver cancer in the United States and around 76% of those men and 36% of those women die from the disease. This malignant tumor is more prevalent in patients with chronic liver disease, especially in individuals with cirrhosis, fatty liver, alcoholic hepatitis or in those with Hepatitis B and C infection.
As for hepatitis itself, the overall review of liver diseases throughout 2020 alone indicates the following:
Liver Cancer Statistics
Liver Cancer is a more common diagnosis in men, but women can also be affected by this disease.
According to the World Health Organization statistics, the number of incident cases of liver cancer in 2020 was the highest in Eastern and South-Central Asia, Northern America and Northern Africa. The highest mortality rate was estimated in Eastern Asia and South-Central Asia.
Global burden of primary liver cancer in 2020 and predictions to 2040
The number of new cases and deaths from liver cancer could rise by >55% by 2040. Predicted percentage change (absolute numbers are shown above bars) of new cases and deaths from primary liver cancer between 2020 and 2040, by Human Development Index (HDI) is shown below.
There are now 2552 ongoing studies conducted in the world on the matter of liver diseases:
Cromos Pharma has a strong track record in managing clinical trials designed to find effective treatments for liver disease and a wide-ranging expertise in clinical research on this subject. If you would like to learn more about liver diseases and the latest clinical trials, here are some helpful links:
- National Cancer Institute
- National Liver Foundation
- The International Association for the Study of the Liver
- American Association for the Study of Liver Diseases
- American Liver Foundation
About Cromos Pharma
Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic indications. Our expert team, comprised of 95% MDs, has extensive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
Cromos Pharma has experience in delivering success in a wide range of trial types, from biosimilars and generics, to successfully managing trials of novel therapeutics in a wide range of clinical indications. Our team provides full-service solutions to international pharma and biotech companies in high-recruiting regions, assuring exceptional data quality. Cromos Pharma combines global expertise with in-depth experience and knowledge in the US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Türkiye to offer exceptional patient recruitment. Our team has met or reduced enrollment timelines in 95% of conducted trials.
We provide accelerated study start-up timelines in our regions of operation. Regulatory inspections by FDA and EMA and site audits attest to the highest quality of our clinical data.
Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is located in Portland, Oregon, USA and its European HQ is in Dublin, Ireland.